BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chiu YH, Spierings J, de Jong PA, Hoesein FM, Grutters JC, van Laar JM, Voortman M. Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. Respir Med 2021;187:106579. [PMID: 34438351 DOI: 10.1016/j.rmed.2021.106579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Niitsu T, Fukushima K, Komukai S, Takata S, Abe Y, Nii T, Kuge T, Iwakoshi S, Shiroyama T, Miyake K, Tujino K, Tanizaki S, Iwahori K, Hirata H, Miki K, Yanagawa M, Takeuchi N, Takeda Y, Kida H, Kumanogoh A. Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease. RMD Open 2023;9. [PMID: 36690385 DOI: 10.1136/rmdopen-2022-002667] [Reference Citation Analysis]
2 Piotrowski W, Martusewicz-boros M, Białas A, Barczyk A, Batko B, Błasińska K, Boros P, Górska K, Grzanka P, Jassem E, Jastrzębski D, Kaczyńska J, Kowal-bielecka O, Kucharz E, Kuś J, Kuźnar-kamińska B, Kwiatkowska B, Langfort R, Lewandowska K, Mackiewicz B, Majewski S, Makowska J, Miłkowska-dymanowska J, Puścińska E, Siemińska A, Sobiecka M, Soroka-dąda R, Szołkowska M, Wiatr E, Ziora D, Śliwiński P. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis. Advances in Respiratory Medicine 2022;90:425-450. [DOI: 10.3390/arm90050052] [Reference Citation Analysis]
3 Tsujii A, Isoda K, Yoshimura M, Nakabayashi A, Kim D, Tamada T, Yamamoto K, Ohshima S. Comparison of safety and efficacy between Janus kinase inhibitors and abatacept for rheumatoid arthritis-associated interstitial lung disease.. [DOI: 10.21203/rs.3.rs-2110699/v1] [Reference Citation Analysis]
4 Yamakawa H, Toyoda Y, Baba T, Kishaba T, Fukuda T, Takemura T, Kuwano K. Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review. JCM 2022;11:3835. [DOI: 10.3390/jcm11133835] [Reference Citation Analysis]
5 Yeh J, Hung T, Lin C, Chen T, Liw P, Yu Y, Kao C. Colchicine Is a Weapon for Managing the Heart Disease Among Interstitial Lung Disease With Viral Infection: Have We Found the Holy Grail? Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.925211] [Reference Citation Analysis]
6 Yeh J, Syue S, Sun Y, Yeh Y, Zheng Y, Lin C, Hsu CY, Kao C. Hydroxychloroquine on the Pulmonary Vascular Diseases in Interstitial Lung Disease: Immunologic Effects, and Virus Interplay. Biomedicines 2022;10:1290. [DOI: 10.3390/biomedicines10061290] [Reference Citation Analysis]
7 Chiu Y, Chu C, Lu C, Liu F, Tang S, Chu S, Kuo S, Chen H. KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case–Control Study. JIR 2022;Volume 15:2255-62. [DOI: 10.2147/jir.s352085] [Reference Citation Analysis]